Urethritis

Microbix Presents Results of STI Test Controls at ASM Microbe

Retrieved on: 
Tuesday, June 13, 2023

At ASM Microbe, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.

Key Points: 
  • At ASM Microbe, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.
  • Microbix will thereby showcase its ever-growing portfolio of QAPs that help ensure the accuracy of antigen and nucleic acid (i.e., “PCR”) tests and their workflows.
  • Using innovative and proprietary methods, Microbix created and manufactured such materials – including for five AMR variants of Mgen.
  • Formatted onto COPAN® FLOQSwabs®, the resulting Microbix QAPs were then used to validate and support novel tests for AMR detection, namely the SpeeDx Pty.

Global Hematuria Treatment Market Forecast to 2028 - COVID-19 Impact and Analysis - ResearchAndMarkets.com

Retrieved on: 
Monday, January 31, 2022

The "Hematuria Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hematuria Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The hematuria treatment market is projected to reach US$ 1,103.61 million by 2028 from US$ 932.89 million in 2021; it is estimated to grow at a CAGR of 2.4% from 2021 to 2028.
  • Based on treatment, the hematuria treatment market is segmented into drugs, therapies, and others.
  • Based on type, the hematuria treatment market is segmented into macroscopic hematuria, microscopic hematuria, idiopathic hematuria, and jogger's hematuria.

New CDC Guidelines Endorse Opt-Out Screening for Two of the Most Common Sexually Transmitted Infections (STIs), Recommend Nucleic Acid Testing for Mycoplasma Genitalium

Retrieved on: 
Monday, July 26, 2021

For the first time, CDC guidelines also defined specific populations (men with recurrent urethritis and women with recurrent cervicitis) to be tested for Mycoplasma genitalium and recommended nucleic-acid amplification testing (NAAT) for detection.

Key Points: 
  • For the first time, CDC guidelines also defined specific populations (men with recurrent urethritis and women with recurrent cervicitis) to be tested for Mycoplasma genitalium and recommended nucleic-acid amplification testing (NAAT) for detection.
  • The 2015 CDC guidelines included M. genitalium as an emerging issue, but no FDA-cleared NAATs were available at that time11.
  • Hologic was first to market in 2019 with a NAAT for M. genitalium, and Hologics Aptima Mycoplasma genitalium Assay is specifically noted in the current guidelines1.
  • No FDA-cleared M. genitalium tests are available in the U.S. that detect antibiotic resistance, although Hologic is working to develop one.